Safety and Efficacy of TAK-715 in Subjects With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of TAK-715, twice daily
(BID), in the treatment of rheumatoid arthritis signs and symptoms in patients with a partial
response to methotrexate.